Despite its relatively low profile since it kicked off its third phase last spring, the Broad Institute's RNAi Consortium is proceeding apace, although its mission has expanded beyond its initial focus of just RNAi.
While the exact goals of the so-called TRC3 have yet to be defined, the initiative expects that these will include the expansion of its scope to include reagents targeting non-coding RNAs.
CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.
In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.
